Last reviewed · How we verify
IM risperidone
IM risperidone is an intramuscular long-acting formulation of the atypical antipsychotic risperidone, which blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.
IM risperidone is an intramuscular long-acting formulation of the atypical antipsychotic risperidone, which blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Schizoaffective disorder, Bipolar disorder maintenance treatment.
At a glance
| Generic name | IM risperidone |
|---|---|
| Sponsor | US Department of Veterans Affairs |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Risperidone antagonizes dopamine D2 receptors in mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis, while also blocking serotonin 5-HT2A receptors which may enhance antipsychotic efficacy and reduce extrapyramidal side effects. The intramuscular depot formulation provides sustained drug release over weeks, improving medication adherence in patients with schizophrenia and other psychotic disorders.
Approved indications
- Schizophrenia
- Schizoaffective disorder
- Bipolar disorder maintenance treatment
Common side effects
- Injection site pain or reaction
- Extrapyramidal symptoms (tremor, rigidity, akathisia)
- Weight gain
- Prolactin elevation
- Sedation
- Orthostatic hypotension
Key clinical trials
- Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia (PHASE1)
- A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (PHASE4)
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
- Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia (PHASE1)
- Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension (PHASE3)
- Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia (PHASE3)
- Comparative Bioavailability of Risperidone. (PHASE1)
- Comparative Bioavailability of Risperidone (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IM risperidone CI brief — competitive landscape report
- IM risperidone updates RSS · CI watch RSS
- US Department of Veterans Affairs portfolio CI